Tenapanor Nears US Approval for Hyperphosphatemia in Dialysis

The FDA granted an appeal to an earlier decision, resetting tenapanor on a path toward approval for treating hyperphosphatemia in patients undergoing dialysis.

Related Keywords

Saint Louis University ,Missouri ,United States ,Kevin Martin ,Office Of New Drugs ,Renal Advisory Committee ,Drug Administration ,Indiana University Hospital ,Advisory Committee ,Division Of Cardiology ,Division Of Nephrology At Saint Louis University ,New Drug Application ,New Drugs ,Kidney Disease ,Improving Global Outcomes ,Hemodialysis ,Vascular Access ,Kidney Dialysis ,Renal Dialysis ,Renal Failure ,Enal Insufficiency ,Idney Insufficiency ,Kidney Failure ,Dialysis ,Hyperphosphatemia ,Chronic Renal Failure ,Hronic Kidney Failure ,Hronic Kidney Disease Ckd ,Chronic Kidney Disease ,Kd ,Renal Disease ,Kidney Disorder ,Renal Disorder ,Ephropathy ,Grant ,Kidneys ,Boards ,Smle ,Us Food And Drug Administr ,